Combining Chemotherapy with Immunotherapy in Colorectal Cancer: A Review

(E-pub Ahead of Print)

Author(s): John Thomas Palathingal*, Basil Sunny, Vismaya Vijayan

Journal Name: Clinical Cancer Drugs

Become EABM
Become Reviewer
Call for Editor


American Cancer Society estimates that about 1 in 21 men and 1 in 23 women in US will develop colorectal cancer during their lifetime. Due to the advances in screening and treatment modalities, the mortality rate has reduced. Rising resistance to treatment have directed the focus towards different approaches as combination therapies involving different treatment techniques available. One such approach is chemo-immunotherapy that targets to modulate TIME and improve the response to immunotherapy. The chemo-immunotherapy has shown a positive impact in improving the outcome of CRC treatment. The ensemble of results discussed herein supports the role of biomarkers in determining the most effective treatment algorithm. A comprehensive knowledge about the off-target effects of the cytotoxic drugs helps in designing more efficacious combined treatment. The time-window for optimal combination must also be considered carefully.

Keywords: Combination therapy, colorectal cancer, chemo-immunotherapy, biomarkers, CRC treatment, cytotoxic drugs

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 29 October, 2020
(E-pub Ahead of Print)
DOI: 10.2174/2212697X07999201029200025
Price: $95

Article Metrics

PDF: 232